Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to -$6.8 million.

  • Cue Biopharma's Cash from Investing Activities fell 700612.24% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.9 million, marking a year-over-year decrease of 2114848.48%. This contributed to the annual value of $32000.0 for FY2024, which is 9987.2% down from last year.
  • As of Q3 2025, Cue Biopharma's Cash from Investing Activities stood at -$6.8 million, which was down 700612.24% from -$27000.0 recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Cash from Investing Activities registered a high of $15.0 million during Q1 2023, and its lowest value of -$29.5 million during Q3 2022.
  • Its 5-year average for Cash from Investing Activities is $143750.6, with a median of -$10500.0 in 2021.
  • Over the last 5 years, Cue Biopharma's Cash from Investing Activities had its largest YoY gain of 97817788.65% in 2022, and its largest YoY loss of 26826363.64% in 2022.
  • Over the past 5 years, Cue Biopharma's Cash from Investing Activities (Quarter) stood at $511.0 in 2021, then skyrocketed by 978177.89% to $5.0 million in 2022, then grew by 0.02% to $5.0 million in 2023, then tumbled by 100.02% to -$1000.0 in 2024, then plummeted by 676700.0% to -$6.8 million in 2025.
  • Its Cash from Investing Activities stands at -$6.8 million for Q3 2025, versus -$27000.0 for Q2 2025 and -$150000.0 for Q1 2025.